artg listing and ce mark, page-4

Thanks for this contribution Charles, though I assume you mean "was not".

Truth me told I was expecting these approvals, but I am glad the market likes it.

What I liked about this announcement was this bit: "reports the percentage of the liver that is fat. It is the first and currently the only FDA approved method for the quantitative measurement of liver fat that has been validated against independent measurements of fat in liver biopsy specimens in a clinical study."

I know Ferriscan has competition but if HepaFat scan does not that is great news. It will be a while before we get to grow revenue from patients to suitable levels, but if there is no competition that bodes very well for getting clinical trial business for HepaFat Scan.